Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin / Philippe Marque in Annals of physical and rehabilitation medicine, Vol. 62, n°4 (Juillet 2019)  

Public ISBD [article]  inAnnals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 207-213 Titre : Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin Type de document : texte imprimé Auteurs : Philippe Marque ; Angélique Denis ; David Gasq ; Emmanuelle Chaleat-Valayer ; Alain P. Yelnik ; Cyrille Colin ; Botuloscope Group ; Dominic Pérennou Année de publication : 2019 Article en page(s) : p. 207-213 Note générale : https://doi.org/10.1016/j.rehab.2019.06.003 Langues : Anglais (eng) Résumé : Background Botuloscope is a cohort study supported by a French public grant and aiming to evaluate a 1-year treatment of the post-stroke spastic upper limb with botulinum toxin type A (BoNT-A) in terms of individual satisfaction with respect to personalized goals and quality of life. Methods This was an open-label prospective, multicentric study (11 French centres) that followed 330 adults [mean (SD) age 53.7 (13.7) years] over 1 year; participants had ranked 5 therapeutic goals at inclusion [mean (SD) 5.1 (7.3) years post-stroke], had severe hemiparesis [median motricity index (MI) 40 (Q1–Q3 24 to 60)], and were assessed at inclusion (M0) and at month 3 (M3) and M12. Outcome criteria were: spasticity, range of motion, pain [visual analog scale (VAS)], motor function [Modified Ashworth Scale (MAS)] and activities (MI; Frenchay Arm Test), and overall satisfaction with the achievement of each goal (VAS) and quality of life (Reintegration to Normal Life Index). Criteria at M0 and M12 were compared. Adverse effects were also collected, as were medication changes. Results The primary goal was comfort and activities for 63% of participants and motor function for 36%. Participants underwent a mean of 2.4 injection sessions, 19% causing adverse effects. The greatest spasticity attenuation occurred with wrist flexors (median decrease in MAS −2 [Q1–Q3; −2 to −1], P < 10−3). Fewer individuals took oral anti-spastic drugs (56% at M12 vs 50% at M0; P < 10−2). Range of motion increased by 16°, on average (13 to 19; P < 10−3) for wrist extension. Pain prevalence decreases at rest (29% at M0 vs. 19% at M12; P < 10−4) and during mobilization (64% vs. 43%; P < 10−4), and fewer participants took analgesics (25% vs. 17%; P < 10−3). Satisfaction was high for the goals “hand hygiene” and “pain release” and moderate for “improvement in upper limb function”. However, function was more improved for participants who selected this goal as the first priority than others (P < 10−2). Overall, 22% had the goal “improving gait and balance”, which was reasonably achieved at M12. Quality of life improved markedly [median 8 (4 to 11) vs. 6 (3 to 10); P < 10−4]. Prevalence of complete dissatisfaction with the first objective was 10% to 15%. Conclusion This is the first long-term follow-up of BoNT-A treatment for upper limb spasticity involving a large cohort independent of industry. Quality of life was improved by treating upper limb spasticity with BoNT-A, even at 5 years post-stroke. Personalizing objectives of the treatment amplified its efficacy. BoNT-A was a powerful analgesic when pain was spasticity-related. Treating the spastic upper limb also improved balance and gait abilities. En ligne : https://www.sciencedirect.com/science/article/pii/S1877065719300776 Permalink : ./index.php?lvl=notice_display&id=84124 [article] Botuloscope: 1-year follow-up of upper limb post-stroke spasticity treated with botulinum toxin [texte imprimé] / Philippe Marque ; Angélique Denis ; David Gasq ; Emmanuelle Chaleat-Valayer ; Alain P. Yelnik ; Cyrille Colin ; Botuloscope Group ; Dominic Pérennou . - 2019 . - p. 207-213. https://doi.org/10.1016/j.rehab.2019.06.003 Langues : Anglais (eng) in Annals of physical and rehabilitation medicine > Vol. 62, n°4 (Juillet 2019) . - p. 207-213 Résumé : Background Botuloscope is a cohort study supported by a French public grant and aiming to evaluate a 1-year treatment of the post-stroke spastic upper limb with botulinum toxin type A (BoNT-A) in terms of individual satisfaction with respect to personalized goals and quality of life. Methods This was an open-label prospective, multicentric study (11 French centres) that followed 330 adults [mean (SD) age 53.7 (13.7) years] over 1 year; participants had ranked 5 therapeutic goals at inclusion [mean (SD) 5.1 (7.3) years post-stroke], had severe hemiparesis [median motricity index (MI) 40 (Q1–Q3 24 to 60)], and were assessed at inclusion (M0) and at month 3 (M3) and M12. Outcome criteria were: spasticity, range of motion, pain [visual analog scale (VAS)], motor function [Modified Ashworth Scale (MAS)] and activities (MI; Frenchay Arm Test), and overall satisfaction with the achievement of each goal (VAS) and quality of life (Reintegration to Normal Life Index). Criteria at M0 and M12 were compared. Adverse effects were also collected, as were medication changes. Results The primary goal was comfort and activities for 63% of participants and motor function for 36%. Participants underwent a mean of 2.4 injection sessions, 19% causing adverse effects. The greatest spasticity attenuation occurred with wrist flexors (median decrease in MAS −2 [Q1–Q3; −2 to −1], P < 10−3). Fewer individuals took oral anti-spastic drugs (56% at M12 vs 50% at M0; P < 10−2). Range of motion increased by 16°, on average (13 to 19; P < 10−3) for wrist extension. Pain prevalence decreases at rest (29% at M0 vs. 19% at M12; P < 10−4) and during mobilization (64% vs. 43%; P < 10−4), and fewer participants took analgesics (25% vs. 17%; P < 10−3). Satisfaction was high for the goals “hand hygiene” and “pain release” and moderate for “improvement in upper limb function”. However, function was more improved for participants who selected this goal as the first priority than others (P < 10−2). Overall, 22% had the goal “improving gait and balance”, which was reasonably achieved at M12. Quality of life improved markedly [median 8 (4 to 11) vs. 6 (3 to 10); P < 10−4]. Prevalence of complete dissatisfaction with the first objective was 10% to 15%. Conclusion This is the first long-term follow-up of BoNT-A treatment for upper limb spasticity involving a large cohort independent of industry. Quality of life was improved by treating upper limb spasticity with BoNT-A, even at 5 years post-stroke. Personalizing objectives of the treatment amplified its efficacy. BoNT-A was a powerful analgesic when pain was spasticity-related. Treating the spastic upper limb also improved balance and gait abilities. En ligne : https://www.sciencedirect.com/science/article/pii/S1877065719300776 Permalink : ./index.php?lvl=notice_display&id=84124

Exemplaires (1)

Cote	Support	Localisation	Section	Disponibilité
Revue	Revue	Centre de Documentation HELHa Campus Montignies	Armoires à volets	Document exclu du prêt - à consulter sur place Exclu du prêt

---

1 (1 - 1 / 1)